Skip to Main Content

Author Details

David L DeMets
University of Wisconsin
1971
240
75
PMIDPaper TitleJournal TitlePublished Year
37749420Training New DMC Members: A Call to Action.Ther Innov Regul Sci2024
37749420Training New DMC Members: A Call to Action.Ther Innov Regul Sci2024
36932245Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial.Nat Med2023
37069466The Data Monitoring Committee: A Collective or a Collection?Ther Innov Regul Sci2023
36932245Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial.Nat Med2023
37231737Bringing data monitoring committee charters into the sunlight.Clin Trials2023
37231737Bringing data monitoring committee charters into the sunlight.Clin Trials2023
37069466The Data Monitoring Committee: A Collective or a Collection?Ther Innov Regul Sci2023
34693741Data monitoring committee interim reports: We must get there soon!Clin Trials2022
36041912Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.J Am Coll Cardiol2022
36030328Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER.Nat Med2022
36029467Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.Circ Heart Fail2022
36027570Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.N Engl J Med2022
35490339The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF.Eur J Heart Fail2022
36258219Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19.Trials2022
36522606Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial.Nat Med2022
35301133The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE study.Contemp Clin Trials2022
34856173Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials.Lancet Diabetes Endocrinol2022
34437834Updates on Hydroxychloroquine in Prevention and Treatment of COVID-19.Am J Med2022
35147927Ivermectin in COVID-19: The Case for a Moratorium on Prescriptions.Ther Innov Regul Sci2022
35114173Updates for Health Providers on Monoclonal Antibodies for COVID-19: Less Promising Adjunct and Never an Alternative to Vaccinations.Am J Med2022
35241246Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.JACC Heart Fail2022
34693741Data monitoring committee interim reports: We must get there soon!Clin Trials2022
35490339The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF.Eur J Heart Fail2022
36522606Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial.Nat Med2022
36041912Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.J Am Coll Cardiol2022
36030328Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER.Nat Med2022
36029467Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.Circ Heart Fail2022
36027570Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.N Engl J Med2022
36258219Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19.Trials2022
34856173Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials.Lancet Diabetes Endocrinol2022
35147927Ivermectin in COVID-19: The Case for a Moratorium on Prescriptions.Ther Innov Regul Sci2022
35241246Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.JACC Heart Fail2022
35114173Updates for Health Providers on Monoclonal Antibodies for COVID-19: Less Promising Adjunct and Never an Alternative to Vaccinations.Am J Med2022
35301133The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE study.Contemp Clin Trials2022
34437834Updates on Hydroxychloroquine in Prevention and Treatment of COVID-19.Am J Med2022
33275134Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.JAMA2021
34051124Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.Eur J Heart Fail2021
33992570The Addition of a Defibrillator to Resynchronization Therapy Decreases Mortality in Patients With Nonischemic Cardiomyopathy.JACC Heart Fail2021
34337584Genomic surveillance to combat COVID-19: challenges and opportunities.Lancet Microbe2021
34314121COVID-19 control in the United States: the case for masking.Am J Manag Care2021
33275134Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.JAMA2021
34952844Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit-risk ratio, not age.Fam Med Community Health2021
35005713Monitoring clinical trials in infectious diseases.J Allergy Infect Dis2021
34952844Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit-risk ratio, not age.Fam Med Community Health2021
35005713Monitoring clinical trials in infectious diseases.J Allergy Infect Dis2021
33992570The Addition of a Defibrillator to Resynchronization Therapy Decreases Mortality in Patients With Nonischemic Cardiomyopathy.JACC Heart Fail2021
34314121COVID-19 control in the United States: the case for masking.Am J Manag Care2021
34337584Genomic surveillance to combat COVID-19: challenges and opportunities.Lancet Microbe2021
34051124Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.Eur J Heart Fail2021
  • 1 - 50 of 480

Recommended Authors

Michael Fralick
University of Toronto
Career Start Year 2007
Number of shared co-authors 1
Rickey E Carter
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 8
Lu Tian
Stanford University
Career Start Year 2001
Number of shared co-authors 2
Julie A Stoner
The University of Oklahoma Health Sciences Center
Career Start Year 1999
Number of shared co-authors 0
Chi-Hong Tseng
David Geffen School of Medicine, University of California los angeles
Career Start Year 1998
Number of shared co-authors 1
Scott M Berry
University of Kansas Medical Center
Career Start Year 1998
Number of shared co-authors 3
Manisha Desai
Stanford University
Career Start Year 1997
Number of shared co-authors 8
Paul J Nietert
Medical University of South Carolina
Career Start Year 1996
Number of shared co-authors 9
Matthew S Mayo
The University of Kansas Medical Center
Career Start Year 1996
Number of shared co-authors 3
Stephen E Kimmel
University of Florida
Career Start Year 1995
Number of shared co-authors 6
Hung-Mo Lin
Icahn School of Medicine at Mount Sinai
Career Start Year 1995
Number of shared co-authors 1
George Tomlinson
University Health Network
Career Start Year 1994
Number of shared co-authors 2
John P A Ioannidis
Stanford University
Career Start Year 1994
Number of shared co-authors 9
Chul Ahn
University of Texas Southwestern Medical Center
Career Start Year 1989
Number of shared co-authors 5
Jesse A Berlin
Rutgers University School of Public Health
Career Start Year 1988
Number of shared co-authors 9
Til St??rmer
University of North Carolina at Chapel Hill
Career Start Year 1988
Number of shared co-authors 4
Lisa A Weissfeld
The Clinical Research, University of Pittsburgh
Career Start Year 1985
Number of shared co-authors 1
Robin Ruthazer
Tufts Clinical and Translational Science Institute, 7Tufts Medical Center
Career Start Year 1983
Number of shared co-authors 5
Karen Byth
Westmead Hospital
Career Start Year 1983
Number of shared co-authors 0
Robert A Parker
Massachusetts General Hospital
Career Start Year 1982
Number of shared co-authors 3
Elizabeth R DeLong
Duke University
Career Start Year 1982
Number of shared co-authors 22
Donald A Berry
MD Anderson Cancer Center
Career Start Year 1980
Number of shared co-authors 6
David A Schoenfeld
Mass General Hospital
Career Start Year 1977
Number of shared co-authors 6
Peter Peduzzi
Yale Center for Analytical Sciences, Yale School of Public Health
Career Start Year 1977
Number of shared co-authors 2
Barbara C Tilley
University of Texas Health Science Center, School of Public Health at Houston
Career Start Year 1977
Number of shared co-authors 3
Alexander M Walker
Harvard T.H. Chan School of Public Health
Career Start Year 1975
Number of shared co-authors 2
Frank E Harrell
Vanderbilt University School of Medicine
Career Start Year 1974
Number of shared co-authors 17
Judith D Goldberg
NYU Grossman School of Medicine
Career Start Year 1974
Number of shared co-authors 3
Brian L Strom
Center for Pharmacoepidemiology and Treatment Science, Rutgers University
Career Start Year 1970
Number of shared co-authors 3

Collaborators

Ronald Klein
University of Wisconsin School of Medicine and Public Health
Co-authored papers 23
Mikhail Kosiborod
Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City
Co-authored papers 18
Erik Magnus Ohman
Duke University Medical Center-Duke Clinical Research Institute
Co-authored papers 14
Robert M Califf
From the National Institutes of Health
Co-authored papers 13
Ralph G Brindis
University of California san francisco
Co-authored papers 12
Adrian F Hernandez
Duke University Medical Center
Co-authored papers 11
Marc S Sabatine
Brigham and Women's Hospital
Co-authored papers 11
Rudolf A de Boer
Co-authored papers 11
Milton Packer
Co-authored papers 10
Lesley H Curtis
Duke Clinical Research Institute
Co-authored papers 9
Akshay S Desai
Brigham and Women's Hospital, Harvard Medical School
Co-authored papers 9
Susan J Pressler
Indiana University
Co-authored papers 9
Carolyn S P Lam
Duke-NUS Medical School
Co-authored papers 8
Arthur M Feldman
Co-authored papers 7
Mark A Creager
Dartmouth-Hitchcock Medical Center, Geisel School of Medicine at Dartmouth
Co-authored papers 7
Elliott M Antman
Co-authored papers 5
Eric D Peterson
University of Texas Southwestern Medical Center
Co-authored papers 5
James H Ware
Harvard School of Public Health
Co-authored papers 5
Salim Yusuf
Co-authored papers 5
Donald C Allred
Co-authored papers 4
Barry M Massie
University of California at San Francisco
Co-authored papers 4
Deepak L Bhatt
Icahn School of Medicine at Mount Sinai Health System
Co-authored papers 4
Matthew T Roe
Duke Clinical Research Institute, Duke University
Co-authored papers 4
Michael J Pencina
Duke University Medical Center
Co-authored papers 3
Kenneth W Mahaffey
Stanford University Medical School
Co-authored papers 3
Gregg C Fonarow
David Geffen School of Medicine, University of California, Los Angeles Medical Center
Co-authored papers 3
John Michael Gaziano
VA Boston Healthcare System
Co-authored papers 3
Robert Temple
Co-authored papers 3
Veronica Clavijo Jordan
Harvard Medical School
Co-authored papers 3
Mitchell H Gail
Co-authored papers 3
Release 1.2